XNAS · Healthcare · Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | 0.27 | 0.18 | -33.33% | $204.9M | ❌ Miss | +0.00% | +1.62% | — |
| 2026-02-26 | Q4 2025 | 0.34 | 0.14 | -58.82% | $192.6M | ❌ Miss | +0.03% | -6.05% | +2.75% |
| 2025-11-03 |
| Q3 2025 |
| 0.22 |
| 2.43 |
| +1004.55% |
| $161.7M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-03 | Q4 2024 | 0.08 | 0.15 | +87.50% | $108.2M | ✅ Beat | +3.49% | +13.97% | +15.69% |
| 2024-11-04 | Q3 2024 | 0.03 | 0.02 | -33.33% | $83.9M | ❌ Miss | +6.16% | +26.19% | +39.08% |
| 2024-08-06 | Q2 2024 | -0.05 | 0.04 | +180.00% | $73.5M | ✅ Beat | -2.87% | +3.16% | +4.28% |
| 2024-05-01 | Q1 2024 | -0.04 | -0.07 | -75.00% | $63.5M | ❌ Miss | +3.40% | +7.81% | +2.64% |
| 2024-02-28 | Q4 2023 | -0.10 | -0.09 | +10.00% | $44.0M | ✅ Beat | -2.33% | +3.40% | -16.22% |
Showing last 8 quarters.